ArticleFrontiers in immunology2026
Identification of FTO as a key m6A demethylase linking immune dysregulation to sepsis pathogenesis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CD63Frontiers in cellular and infection microbiology · 2026Article
- FTO in cardiovascular diseases: mechanisms, context dependence, and translational opportunities.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a life-threatening disorder characterized by multiple organ dysfunction caused by dysregulated host responses to infection. The present study aimed to identify potential diagnostic biomarkers for sepsis and elucidate their molecular mechanisms through comprehensive bioinformatics and experimental analyses. Methods: Five publicly available transcriptomic datasets (GSE13904, GSE26440, GSE28750, GSE95233, and GSE57065) containing sepsis and healthy control samples were utilized in the study. After quality control and normalization, the samples were divided into training and validation cohorts. Fourteen machine learning algorithms were applied to the training cohort to identify robust diagnostic biomarkers, and their predictive performance was subsequently verified in the validation cohorts. Single-cell RNA sequencing (scRNA-seq) data were further analyzed to determine the cellular distribution of the identified regulators among immune cell subsets. Results: In total, the least absolute shrinkage and selection operator (LASSO) model exhibited the best performance in the validation set, demonstrating high reliability. Through consensus feature selection across multiple models, the m Conclusion: FTO, identified through consensus machine learning approaches, could serve as a potential diagnostic biomarker and m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.